Loading news article.

FilingSEC EDGAR8-K

Silexion Reports Positive Preclinical Findings for SIL204

Sep 28, 2026, 08:46 ET · SEC accepted

StagePreclinical

Filing content

Silexion Therapeutics announced positive preclinical findings demonstrating that its lead RNAi candidate, SIL204, utilizes native lipid transport pathways for efficient cellular delivery in KRAS-driven cancers.

AI summary of the filing. Please also check the source.

Related companies

Silexion Therapeutics CorpSLXNView stock

Analyzed by WAPE AI.

Preparing English content…

Repost

Comments —

Loading comments…